The Level of Ets-1 Protein Is Regulated by Poly(ADP-Ribose) Polymerase-1 (PARP-1) in Cancer Cells to Prevent DNA Damage

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Legrand, Arnaud J ^a   Choul Li, Souhaila ^a,d   Spriet, Corentin ^a   Idziorek, Thierry ^b   Vicogne, Dorothée ^a   Drobecq, Hervé ^a   Dantzer, Françoise ^c   Villeret, Vincent ^a   Aumercier, Marc ^a  

^a UNIV LILLE   (France)

^b Institut de Recherche sur le Cancer de Lille   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d FACULTÉ DES SCIENCES   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; STROMELYSIN; TRANSCRIPTION FACTOR ETS 1;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CATALYSIS; CELL DEATH; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL NUCLEUS; CELLS, CULTURED; DNA DAMAGE; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, KNOCKOUT; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEIN C-ETS-1; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSCRIPTION, GENETIC;

EID: 84873556805     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055883     Document Type: Article

References (55)

1. de Nigris F, Mega T, Berger N, Barone MV, Santoro M, et al. (2001) Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. Cancer Res 61: 2267-2275.
2. Higuchi T, Bartel FO, Masuya M, Deguchi T, Henderson KW, et al. (2007) Thymomegaly, microsplenia, and defective homeostatic proliferation of peripheral lymphocytes in p51-Ets1 isoform-specific null mice. Mol Cell Biol 27: 3353-3366.
3. Kita D, Takino T, Nakada M, Takahashi T, Yamashita J, et al. (2001) Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin alpha5 expression in U251 glioma cell line. Cancer Res 61: 7985-7991.
4. Lulli V, Romania P, Morsilli O, Gabbianelli M, Pagliuca A, et al. (2006) Overexpression of Ets-1 in human hematopoietic progenitor cells blocks erythroid and promotes megakaryocytic differentiation. Cell Death Differ 13: 1064-1074.
5. Taniguchi H, Fujiwara Y, Doki Y, Sugita Y, Sohma I, et al. (2007) Gene therapy using ets-1 transcription factor decoy for peritoneal dissemination of gastric cancer. Int J Cancer 121: 1609-1617.
6. Teruyama K, Abe M, Nakano T, Iwasaka-Yagi C, Takahashi S, et al. (2001) Role of transcription factor Ets-1 in the apoptosis of human vascular endothelial cells. J Cell Physiol 188: 243-252.
7. Dittmer J, (2003) The biology of the Ets1 proto-oncogene. Mol Cancer 2: 29.
8. Raffetseder U, Wernert N, Ostendorf T, van Roeyen C, Rauen T, et al. (2004) Mesangial cell expression of proto-oncogene Ets-1 during progression of mesangioproliferative glomerulonephritis. Kidney Int 66: 622-632.
9. Redlich K, Kiener HP, Schett G, Tohidast-Akrad M, Selzer E, et al. (2001) Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor alpha. Arthritis Rheum 44: 266-274.
10. Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, et al. (2001) Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res 7: 551-557.
11. Katayama S, Nakayama T, Ito M, Naito S, Sekine I, (2005) Expression of the ets-1 proto-oncogene in human breast carcinoma: differential expression with histological grading and growth pattern. Histol Histopathol 20: 119-126.
12. Nakayama T, Ito M, Ohtsuru A, Naito S, Sekine I, (2001) Expression of the ets-1 proto-oncogene in human colorectal carcinoma. Mod Pathol 14: 415-422.
13. Takanami I, Takeuchi K, Karuke M, (2001) Expression of ETS-1 is correlated with urokinase-type plasminogen activator and poor prognosis in pulmonary adenocarcinoma. Tumour Biol 22: 205-210.
14. Lee GM, Donaldson LW, Pufall MA, Kang HS, Pot I, et al. (2005) The structural and dynamic basis of Ets-1 DNA binding autoinhibition. J Biol Chem 280: 7088-7099.
15. Pufall MA, Graves BJ, (2002) Autoinhibitory domains: modular effectors of cellular regulation. Annu Rev Cell Dev Biol 18: 421-462.
16. Baillat D, Begue A, Stehelin D, Aumercier M, (2002) ETS-1 transcription factor binds cooperatively to the palindromic head to head ETS-binding sites of the stromelysin-1 promoter by counteracting autoinhibition. J Biol Chem 277: 29386-29398.
17. Baillat D, Laitem C, Leprivier G, Margerin C, Aumercier M, (2009) Ets-1 binds cooperatively to the palindromic Ets-binding sites in the p53 promoter. Biochem Biophys Res Commun 378: 213-217.
18. Leprivier G, Baillat D, Begue A, Hartmann B, Aumercier M, (2009) Ets-1 p51 and p42 isoforms differentially modulate Stromelysin-1 promoter according to induced DNA bend orientation. Nucleic Acids Res 37: 4341-4352.
19. Ji Z, Degerny C, Vintonenko N, Deheuninck J, Foveau B, et al. (2007) Regulation of the Ets-1 transcription factor by sumoylation and ubiquitinylation. Oncogene 26: 395-406.
20. Choul-li S, Drobecq H, Aumercier M, (2009) DNA-dependent protein kinase is a novel interaction partner for Ets-1 isoforms. Biochem Biophys Res Commun 390: 839-844.
21. Kim MY, Zhang T, Kraus WL, (2005) Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev 19: 1951-1967.
22. Hassa PO, Buerki C, Lombardi C, Imhof R, Hottiger MO, (2003) Transcriptional coactivation of nuclear factor-kappaB-dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1. J Biol Chem 278: 45145-45153.
23. Kanai M, Hanashiro K, Kim SH, Hanai S, Boulares AH, et al. (2007) Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol 9: 1175-1183.
24. Li M, Naidu P, Yu Y, Berger NA, Kannan P, (2004) Dual regulation of AP-2alpha transcriptional activation by poly(ADP-ribose) polymerase-1. Biochem J 382: 323-329.
25. Yap TA, Sandhu SK, Carden CP, de Bono JS, (2011) Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 61: 31-49.
26. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, et al. (2012) PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res 72: 1608-1613.
27. Cohen-Armon M, Visochek L, Rozensal D, Kalal A, Geistrikh I, et al. (2007) DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol Cell 25: 297-308.
28. Wang H, Fang R, Cho JY, Libermann TA, Oettgen P, (2004) Positive and negative modulation of the transcriptional activity of the ETS factor ESE-1 through interaction with p300, CREB-binding protein, and Ku 70/86. J Biol Chem 279: 25241-25250.
29. Soldatenkov VA, Albor A, Patel BK, Dreszer R, Dritschilo A, et al. (1999) Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor. Oncogene 18: 3954-3962.
30. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, et al. (2011) Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19: 664-678.
31. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575.
32. Laitem C, Choul-Li S, Baillat D, Begue A, Aumercier M, (2008) Efficient system for biotinylated recombinant Ets-1 production in Escherichia coli: a useful tool for studying interactions between Ets-1 and its partners. Protein Expr Purif 62: 53-63.
33. Laitem C, Leprivier G, Choul-Li S, Begue A, Monte D, et al. (2009) Ets-1 p27: a novel Ets-1 isoform with dominant-negative effects on the transcriptional properties and the subcellular localization of Ets-1 p51. Oncogene 28: 2087-2099.
34. Baillat D, Leprivier G, Regnier D, Vintonenko N, Begue A, et al. (2006) Stromelysin-1 expression is activated in vivo by Ets-1 through palindromic head-to-head Ets binding sites present in the promoter. Oncogene 25: 5764-5776.
35. Huang D, Wang Y, Yang C, Liao Y, Huang K, (2009) Angiotensin II promotes poly(ADP-ribosyl)ation of c-Jun/c-Fos in cardiac fibroblasts. J Mol Cell Cardiol 46: 25-32.
36. Madison DL, Stauffer D, Lundblad JR, (2011) The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest. DNA Repair (Amst) 10: 1003-1013.
37. Kars MD, Iseri OD, Gunduz U, (2010) Drug resistant breast cancer cells overexpress ETS1 gene. Biomed Pharmacother 64: 458-462.
38. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
39. Ledford H, (2012) Drug candidates derailed in case of mistaken identity. Nature 483: 519.
40. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, et al. (2012) Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 30: 283-288.
41. Luo X, Kraus WL, (2012) On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 26: 417-432.
42. Ju BG, Solum D, Song EJ, Lee KJ, Rose DW, et al. (2004) Activating the PARP-1 sensor component of the groucho/TLE1 corepressor complex mediates a CaMKinase IIdelta-dependent neurogenic gene activation pathway. Cell 119: 815-829.
43. Pavri R, Lewis B, Kim TK, Dilworth FJ, Erdjument-Bromage H, et al. (2005) PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of mediator. Mol Cell 18: 83-96.
44. Foulds CE, Nelson ML, Blaszczak AG, Graves BJ, (2004) Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol Cell Biol 24: 10954-10964.
45. Wang Z, Michaud GA, Cheng Z, Zhang Y, Hinds TR, et al. (2012) Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly(ADP-ribosyl)ation-dependent ubiquitination. Genes Dev 26: 235-240.
46. Kang HC, Lee YI, Shin JH, Andrabi SA, Chi Z, et al. (2011) Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. Proc Natl Acad Sci U S A 108: 14103-14108.
47. Lovejoy CA, Xu X, Bansbach CE, Glick GG, Zhao R, et al. (2009) Functional genomic screens identify CINP as a genome maintenance protein. Proc Natl Acad Sci U S A 106: 19304-19309.
48. Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, et al. (2012) PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition. Cancer Discov.
49. Ying S, Hamdy FC, Helleday T, (2012) Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res 72: 2814-2821.
50. Ni W, Zhan Y, He H, Maynard E, Balschi JA, et al. (2007) Ets-1 is a critical transcriptional regulator of reactive oxygen species and p47(phox) gene expression in response to angiotensin II. Circ Res 101: 985-994.
51. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, et al. (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436: 123-127.
52. Weyemi U, Lagente-Chevallier O, Boufraqech M, Prenois F, Courtin F, et al. (2012) ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene 31: 1117-1129.
53. Gebhard C, Stahli BE, Shi Y, Camici GG, Akhmedov A, et al. (2011) Poly(ADP-ribose) polymerase-1 protects from oxidative stress induced endothelial dysfunction. Biochem Biophys Res Commun 414: 641-646.
54. Dantzer F, de La Rubia G, Menissier-De Murcia J, Hostomsky Z, de Murcia G, et al. (2000) Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry 39: 7559-7569.
55. Rocha-Perugini V, Montpellier C, Delgrange D, Wychowski C, Helle F, et al. (2008) The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS One 3: e1866.